Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Kidney Neoplasms × CB-839 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Waldenstrom Macroglobulinemia 1 Solid Tumors 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Colonic Neoplasms 1

Interventions

aldesleukin 39 Sunitinib 36 Cyclophosphamide 29 Nivolumab 28 pembrolizumab 26 Interferon-alpha 25 Everolimus 24 Sorafenib 21 Bevacizumab 20 fludarabine phosphate 19 Ipilimumab 17 Interleukin-2 17 Radiotherapy 16 Peripheral Blood Stem Cell Transplantation 15 Gene Expression Profiling 15 Gemcitabine 15 Filgrastim 15 Axitinib 15 cabozantinib 13 Radiosurgery 12 Blood Specimen Collection 11 temsirolimus 10 fludarabine 10 Doxorubicin 10 Carboplatin 10 sargramostim 8 belzutifan 8 Immunohistochemistry 8 Fluorouracil 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03428217 2023-03-20

CANTATA

Calithera Biosciences, Inc

Phase 2 Completed

444 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡